PMID: 21607646

Venerando A, Pagano MA, Tosoni K, Meggio F, Cassidy D, Stobbart M, Pinna LA, Mehta A
Understanding protein kinase CK2 mis-regulation upon F508del CFTR expression.
Naunyn Schmiedebergs Arch Pharmacol. 2011 May 24., 2011-05-24 [PubMed]
Sentences
No. Mutations Sentence Comment
74 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21607646:74:98
status: NEW
view ABCC7 p.Gly551Asp details
As proof of principle, a new small molecule has recently been reported to re-open the rare mutant G551D CFTR (<5% of alleles) which theoretically cannot transport anions because its nucleotide sandwich is defective in ATP hydrolysis (Accurso et al. 2010). Login to comment
75 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21607646:75:93
status: NEW
view ABCC7 p.Gly551Asp details
In CF, the affected sweat gland duct produces too much sodium and chloride because defective G551D CFTR cannot open its pore to re-absorb chloride which consequently, together with luminal sodium, passes on by the chloride-impermeant apical membrane of the sweat duct onwards to the skin surface. Login to comment
77 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21607646:77:203
status: NEW
view ABCC7 p.Gly551Asp details
That the observed LIMBO reversal is not complete suggests that the pathway from gene to disease is not fully understood and is consistent with this drug`s unexpected effects on CFTR mutants without this G551D-induced ATP hydrolytic defect. Login to comment
79 ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 21607646:79:140
status: NEW
view ABCC7 p.Gly542* details
This drug is claimed to restore full-length CFTR bearing stop mutations that normally induce nonsense-mediated CFTR decay (for example, the G542X stop mutation in CFTR and others like it that together account for about 10% of CFTR mutants). Login to comment
80 ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 21607646:80:103
status: NEW
view ABCC7 p.Gly542* details
At the very least, this drug, which was developed to create read-through at single stop codons such as G542X, should reverse the above 'gold standard` sweat test, but it absolutely fails to do so, thus adding further doubt to our ability to fully understand the path from CFTR defect to disease. Login to comment
98 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21607646:98:125
status: NEW
view ABCC7 p.Gly551Asp details
This idea is challenged by a recent study (Comer et al. 2009) examining lung function in CF patients with the above 'severe` G551D CFTR mutant that is supposedly devoid of any channel activity (Briel et al. 1998) in vitro. Login to comment
102 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21607646:102:72
status: NEW
view ABCC7 p.Gly551Asp details
Thus, we have yet another theory-practice paradox of a dead but present G551D CFTR channel that is normally processed to the apical membrane creating better functioning lungs than those with a F508del CFTR missing channel that is degraded in the ER and probably never reaches the apical membrane. Login to comment
103 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21607646:103:76
status: NEW
view ABCC7 p.Gly551Asp details
At the very least, these patient data challenge the widely held notion that G551D is always a 'severe` CF mutation. Login to comment
104 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21607646:104:90
status: NEW
view ABCC7 p.Gly551Asp details
Those proposing the alternative 'knock-in` network dysfunction model would say that after G551D mutation, the sodium channel may not be as hyperactive as found in F508del CFTR, so we might expect better lungs. Login to comment
105 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21607646:105:24
status: NEW
view ABCC7 p.Gly551Asp details
Yet others suggest that G551D CFTR also fails to inhibit the sodium channel in model systems (Briel et al. 1998), and the latest animal data suggest that the very idea of augmented sodium absorption needs to be treated with caution rather than drugs (Chen et al. 2010). Login to comment